Welcome to our dedicated page for GERON SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
Geron Corp director Dawn Carter Bir received a new stock option grant. On 2026-05-20, she was awarded options to acquire 220,000 shares of Geron common stock at an exercise price of $1.2600 per share, with no cost for the grant itself.
The option covers 220,000 underlying common shares and expires on 2036-05-19. According to the terms, it will vest and become exercisable in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, provided she maintains continuous service with Geron through that date.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin filed an Amendment No. 3 Schedule 13G/A reporting beneficial ownership of 31,720,278 shares of Geron Corp common stock, representing 4.95% of the class. The filing states shared voting and shared dispositive power over those 31,720,278 shares and cites 640,544,661 shares outstanding as of February 20, 2026. The cover identifies Deep Track Capital, LP as the relevant entity for which Mr. Kroin may be considered a control person. The filing is signed and dated May 15, 2026.
Geron Corporation reports Soleus Capital Master Fund, L.P. and affiliated filing of 41,508,659 shares of Common Stock. The filing states these shares represent 6.5% of the class, using 641,520,974 shares outstanding as of May 1, 2026. The ownership is reported as shared voting and dispositive power across Soleus entities and Guy Levy.
Geron Corp reported that EVP and Chief Legal Officer Timothy Williams received a grant of stock options. He was awarded options to buy 2,500,000 shares of Geron common stock at an exercise price of $1.73 per share, expiring on April 12, 2036.
According to the vesting terms, 312,500 shares underlying the option will vest on October 13, 2026, with the remaining shares vesting in equal installments over the following 42 months, assuming he continues serving the company on each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
GERON CORP executive Timothy Williams, EVP and Chief Legal Officer, has filed an initial Form 3 as a reporting person. The available data show no reported transactions or holdings, reflecting a baseline regulatory ownership filing rather than any new buying or selling activity.
Geron Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 20, 2026 at 2:00 p.m. Eastern. Holders of 640,900,330 common shares as of March 26, 2026 may vote.
Proposals include electing three Class III directors, adding 4,500,000 shares to the 2018 Equity Incentive Plan, an advisory vote on executive pay, and ratifying Ernst & Young LLP as auditor for 2026. The meeting will be held online at www.virtualshareholdermeeting.com/GERN2026, where investors can attend, submit questions, and vote using their 16-digit control number.
Spiegel Robert J. reported acquisition or exercise transactions in this Form 4 filing.
Geron Corp director Robert J. Spiegel received 5,243 shares of common stock as part of his board compensation. The shares were granted in lieu of cash for his quarterly board retainer and committee fees, using a reference price of $1.49 per share based on the March 31, 2026 closing price. Following this stock award, he directly holds 199,707 Geron common shares.
The Vanguard Group filed an Amendment No. 1 to a Schedule 13G/A stating it beneficially owns 0 shares of Geron Corp, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries/divisions to report separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.